December 8, 2020
Takeda Pharmaceutical said on December 4 that its investigational agent maribavir (TAK-620) met the primary target in an overseas PIII study for the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection. In the SOLSTICE trial, which was conducted in...read more